Chronic Pain Optimization and Management for Relief and Functionality With TEA in Cirrhosis
A legfontosabb adatok
- Hol
- Ann Arbor és Philadelphia (Egyesült Államok)Mind a 2 helyszín megnézése
Helyszínek itt: Egyesült Államok
- University of MichiganAnn Arbor, Egyesült ÁllamokContact: Melanie TapperNo longer taking part
- University of PennsylvaniaPhiladelphia, Egyesült ÁllamokContact: Richard Mason, PharmDNo longer taking part
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- University of Michigan
- Azonosító
- NCT07820917
- A regiszteradat frissítve
- 2026. szeptember 16.
- Eredeti leírás
This study is being done to better understand how the study team can treat pain for people with cirrhosis and depression.A teljes eredeti leírásKevesebb
COMFORT: Chronic Pain Optimization and Management for Relief and Functionality With TEA in Cirrhosis
This study is being done to better understand how the study team can treat pain for people with cirrhosis and depression.
Enrolled participants on this feasibility study will be randomized to Transcutaneous Electrical Acustimulation (TEA) or sham TEA.
Bevonási feltételek: Diagnosis of cirrhosis - must meet the criteria as outlined in the protocol; Chronic pain (Patient self-reports ≥ 4 on the 0-10 scale for >50% of days within 3- months); Willing to use a Transcutaneous Electrical Acustimulation (TEA) device; Has access to Wi-Fi or a data plan; Has access to a laptop, computer, tablet, or smartphone.
Kizáró feltételek: Expected to undergo liver transplant in next 24 weeks; Implanted pacemaker/defibrillator, spinal implant, or cochlear implant; Dementia and/or severe cognitive impairment; Known allergy to adhesive tape/electrode materials; Model for End-Stage Liver Diseas (MELD) score >25, or total bilirubin >4.0 in a patient on hemodialysis; Unable or unwilling to provide consent; No email address; Deemed unsuitable by the study investigator; Recent hospitalization (>24 hours) or episode of hepatic encephalopathy within the preceding 30 days; Current active suicidal ideation, endorsed at screening (see Section 8.6); Currently pregnant (self-reported).